Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
P/B ratio for Abcam plc (ABCM)
P/B ratio as of 2022: 4.05
According to Abcam plc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.05. At the end of 2021 the company had a P/B ratio of 6.07.
P/B ratio history for Abcam plc from 2002 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 4.05 |
| 2021 | 6.07 |
| 2020 | 0.00 |
| 2019 | 5.50 |
| 2018 | 7.74 |
| 2017 | 7.81 |
| 2016 | 6.48 |
| 2015 | 5.56 |
| 2014 | 4.63 |
| 2013 | 3.77 |
| 2012 | 4.62 |
| 2011 | 4.08 |
| 2010 | 8.42 |
| 2009 | 11.31 |
| 2008 | 14.80 |
| 2007 | 18.28 |
| 2006 | 22.95 |
| 2005 | 28.87 |
| 2004 | 116.09 |
| 2003 | 288.46 |
| 2002 | 757.34 |